List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5897188/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function. Prostate Cancer and Prostatic Diseases, 2022, 25, 238-247.	3.9	2
2	Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes. Journal of Urology, 2022, 207, 1029-1037.	0.4	9
3	Adoption of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer. Advances in Radiation Oncology, 2022, 7, 100877.	1.2	4
4	Locoregional Management and Prognostic Factors in Breast Cancer With Ipsilateral Internal Mammary and Axillary Lymph Node Involvement. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.8	2
5	Patient, physician, and policy factors underlying variation in use of telemedicine for radiation oncology cancer care. Cancer Medicine, 2022, , .	2.8	6
6	Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction. JAMA Surgery, 2022, 157, e220631.	4.3	23
7	Knowledgeâ€based planning for the radiation therapy treatment plan quality assurance for patients with head and neck cancer. Journal of Applied Clinical Medical Physics, 2022, 23, e13614.	1.9	11
8	Proton Accelerated Partial Breast Irradiation: Clinical Outcomes at a Planned Interim Analysis of a Prospective Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2021, 109, 441-448.	0.8	19
9	Influence of Geography on Prostate Cancer Treatment. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1286-1295.	0.8	19
10	Combination of Radiation Therapy andÂShort-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for MenÂWith High- and Intermediate-Risk Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1271-1278.	0.8	10
11	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 953-963.	0.8	6
12	Fiveâ€year outcomes from a prospective comparative effectiveness study evaluating externalâ€beam radiotherapy with or without lowâ€doseâ€rate brachytherapy boost for localized prostate cancer. Cancer, 2021, 127, 1912-1925.	4.1	6
13	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 521-527.	1.6	3
14	A 25-year perspective on the evolution of radiation treatment of urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 577-581.	1.6	0
15	Radiotherapy clinical trial enrollment during the COVID-19 pandemic. Acta Oncológica, 2021, 60, 312-315.	1.8	8
16	Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer, 2020, 126, 506-514.	4.1	21
17	Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 930.e23-930.e32.	1.6	6
18	Predictors of urinary toxicity with MRI-assisted radiosurgery for low-dose-rate prostate brachytherapy, 2020, 19, 574-583.	0.5	13

#	Article	IF	CITATIONS
19	Understanding the Intersection of Working from Home and Burnout to Optimize Post-COVID19 Work Arrangements in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2020, 108, 370-373.	0.8	35
20	Wait and Hurry Up: Radiation Therapy for Prostate Cancer During the COVID-19 Pandemic. International Journal of Radiation Oncology Biology Physics, 2020, 108, 340.	0.8	2
21	Costs and Complications After a Diagnosis of Prostate Cancer Treated With Time-Efficient Modalities: An Analysis of National Medicare Data. Practical Radiation Oncology, 2020, 10, 282-292.	2.1	5
22	Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. JAMA Network Open, 2020, 3, e201255.	5.9	18
23	Increased Frequency of Mesorectal and Perirectal LN Involvement in T4 Prostate Cancers. International Journal of Radiation Oncology Biology Physics, 2020, 107, 982-985.	0.8	12
24	Reply to Multidisciplinary clinics: A possible means to help to eliminate racial disparities in prostate cancer. Cancer, 2020, 126, 2939-2940.	4.1	1
25	Neoadjuvant Radiotherapy to Facilitate Immediate Breast Reconstruction: A Systematic Review and Current Clinical Trials. Annals of Surgical Oncology, 2019, 26, 3312-3320.	1.5	20
26	Mean treatment cost of incident cases of penile cancer for privately insured patients in the United States. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 294.e17-294.e25.	1.6	5
27	Radical prostatectomy or radiotherapy for high―and very highâ€risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment. BJU International, 2019, 124, 811-819.	2.5	28
28	Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. International Journal of Radiation Oncology Biology Physics, 2019, 104, 574-581.	0.8	9
29	Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2019, 104, 790-797.	0.8	56
30	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9–10 Prostate Cancer. European Urology, 2019, 75, 35-41.	1.9	18
31	Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. Practical Radiation Oncology, 2019, 9, e4-e13.	2.1	13
32	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3 + 4 Favorable Intermediate-risk Prostate Cancer. European Urology Focus, 2019, 5, 69-76.	3.1	40
33	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. Journal of Urology, 2019, 201, 528-534.	0.4	57
34	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. Journal of Cardiovascular Imaging, 2019, 27, 268.	0.7	30
35	A component of lobular carcinoma in clinically lymph node–negative patients predicts for an increased likelihood of upstaging to pathologic stage III breast cancer. Advances in Radiation Oncology, 2018, 3, 252-257.	1.2	6
36	Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. European Urology, 2018, 74, 26-33.	1.9	30

#	Article	IF	CITATIONS
37	The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study. Journal of Urology, 2018, 199, 1202-1209.	0.4	49
38	Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Practical Radiation Oncology, 2018, 8, 145-152.	2.1	431
39	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 2018, 131, 517-523.	1.5	13
40	Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 558-567.	1.3	27
41	Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clinical Breast Cancer, 2018, 18, 276-281.	2.4	21
42	Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes. International Journal of Radiation Oncology Biology Physics, 2018, 100, 374-382.	0.8	42
43	Quality of life after brachytherapy or bilateral nerveâ€sparing robotâ€assisted radical prostatectomy for prostate cancer: a prospective cohort. BJU International, 2018, 121, 540-548.	2.5	22
44	Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy ofÂthe Mid 1990s for Localized Prostate Cancer. Urology Practice, 2018, 5, 471-479.	0.5	1
45	Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer, 2018, 124, 1141-1149.	4.1	21
46	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. Journal of Clinical Oncology, 2018, 36, 3411-3430.	1.6	118
47	Racial variation in receipt of quality radiation therapy for prostate cancer. Cancer Causes and Control, 2018, 29, 895-899.	1.8	15
48	Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Practical Radiation Oncology, 2018, 8, 354-360.	2.1	151
49	Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. Journal of Urology, 2018, , .	0.4	16
50	Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures. Practical Radiation Oncology, 2018, 8, 307-316.	2.1	12
51	Racial disparities in guideline-concordant cancer care and mortality in the United States. Advances in Radiation Oncology, 2018, 3, 221-229.	1.2	48
52	Proton Partial Breast Irradiation: Detailed Description of Acute Clinico-Radiologic Effects. Cancers, 2018, 10, 111.	3.7	6
53	Association of Transforming Growth Factor β Polymorphism Câ^'509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer. JAMA Oncology, 2018, 4, 1751.	7.1	34
54	Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, 116-126.	0.8	11

#	Article	IF	CITATIONS
55	Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. European Urology Focus, 2017, 3, 258-264.	3.1	51
56	Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data. Cancer, 2017, 123, 1617-1624.	4.1	24
57	Influence of Age on Guideline-Concordant Cancer Care for Elderly Patients in the United States. International Journal of Radiation Oncology Biology Physics, 2017, 98, 748-757.	0.8	37
58	A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 777-783.	0.8	30
59	Active surveillance in prostate cancer: new efforts, new voices, new hope. BJU International, 2017, 120, 4-5.	2.5	1
60	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e25-542.e32.	1.6	6
61	The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. Urology, 2017, 103, 173-178.	1.0	18
62	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 338-343.	0.8	9
63	Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. JAMA - Journal of the American Medical Association, 2017, 317, 1126.	7.4	261
64	Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy. JAMA Oncology, 2017, 3, 1060.	7.1	62
65	Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial. Advances in Radiation Oncology, 2017, 2, 249-258.	1.2	21
66	A 10-Year Experience with Mastectomy and Tissue Expander Placement to Facilitate Subsequent Radiation and Reconstruction. Annals of Surgical Oncology, 2017, 24, 2965-2971.	1.5	20
67	Factors associated with regional recurrence after lymph node dissection for penile squamous cell carcinoma. BJU International, 2017, 119, 591-597.	2.5	15
68	Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. European Urology, 2017, 72, 307-314.	1.9	19
69	Risk of hospitalisation after primary treatment for prostate cancer. BJU International, 2017, 120, 48-55.	2.5	3
70	Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. Journal of Contemporary Brachytherapy, 2016, 1, 1-6.	0.9	23
71	Outcomes after adjuvant radiation therapy for prostate cancer at a comprehensive cancer center. Journal of Radiation Oncology, 2016, 5, 287-292.	0.7	0
72	Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 637-644.	0.8	1

#	Article	IF	CITATIONS
73	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 2016, 15, 695-700.	0.5	13
74	National sociodemographic disparities in the treatment of highâ€risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 2016, 122, 3371-3377.	4.1	27
75	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 421-428.	4.9	10
76	Disease reclassification risk with stringent criteria and frequent monitoring in men with favourableâ€risk prostate cancer undergoing active surveillance. BJU International, 2016, 118, 68-76.	2.5	27
77	Association Between Treatment at a High-Volume Facility and Improved Survival forÂRadiation-Treated Men With High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 683-690.	0.8	57
78	Trends in Local Therapy Utilization and Cost for Early-Stage Breast Cancer in Older Women: Implications for Payment and Policy Reform. International Journal of Radiation Oncology Biology Physics, 2016, 95, 605-616.	0.8	13
79	Proton Partial-Breast Irradiation for Early-Stage Cancer: Is It Really So Costly?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 49-51.	0.8	15
80	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer, 2016, 122, 1505-1512.	4.1	27
81	The implications of ageing and life expectancy in prostate cancer treatment. Nature Reviews Urology, 2016, 13, 289-295.	3.8	7
82	Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method. Practical Radiation Oncology, 2016, 6, 166-175.	2.1	26
83	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 2016, 118, 95-101.	2.5	45
84	The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. Journal of Urology, 2016, 195, 321-329.	0.4	50
85	Proton Beam Therapy for Localized Prostate Cancer: Results from a Prospective Quality-of-Life Trial. International Journal of Particle Therapy, 2016, 3, 27-36.	1.8	14
86	Prognosis for patients with metastatic breast cancer who achieve a noâ€evidenceâ€ofâ€disease status after systemic or local therapy. Cancer, 2015, 121, 4324-4332.	4.1	34
87	In Reply to Rusthoven and Kavanagh. International Journal of Radiation Oncology Biology Physics, 2015, 91, 680-681.	0.8	Ο
88	Proton partial breast irradiation in the supine position: Treatment description and reproducibility of a multibeam technique. Practical Radiation Oncology, 2015, 5, e283-e290.	2.1	8
89	Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation. JAMA Oncology, 2015, 1, 931.	7.1	216
90	The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. European Urology, 2015, 67, 1019-1025.	1.9	15

#	Article	IF	CITATIONS
91	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 330.e19-330.e25.	1.6	13
92	The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. SpringerPlus, 2015, 4, 36.	1.2	14
93	National Trends in the Recommendation of Radiotherapy After Prostatectomy for Prostate Cancer Before and After the Reporting of a Survival Benefit in March 2009. Clinical Genitourinary Cancer, 2015, 13, e167-e172.	1.9	13
94	Definition and Validation of "Favorable High-Risk Prostate Cancerâ€: Implications for Personalizing Treatment of Radiation-Managed Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 828-835.	0.8	40
95	Does Cancer Literature Reflect Multidisciplinary Practice? A Systematic Review of Oncology Studies in the Medical Literature Over a 20-Year Period. International Journal of Radiation Oncology Biology Physics, 2015, 92, 721-731.	0.8	12
96	Fate of Manuscripts Rejected From the Red Journal. International Journal of Radiation Oncology Biology Physics, 2015, 91, 3-10.	0.8	14
97	Association of androgenâ€deprivation therapy with excess cardiacâ€specific mortality in men with prostate cancer. BJU International, 2015, 116, 358-365.	2.5	66
98	Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 993-998.	4.9	4
99	Quantification of beam complexity in intensityâ€modulated radiation therapy treatment plans. Medical Physics, 2014, 41, 021716.	3.0	106
100	Cancer-Specific Outcomes Among Young Adults Without Health Insurance. Journal of Clinical Oncology, 2014, 32, 2025-2030.	1.6	112
101	Physician Variation in Management of Low-Risk Prostate Cancer. JAMA Internal Medicine, 2014, 174, 1450.	5.1	104
102	Refusal of Curative Radiation Therapy and Surgery Among Patients With Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 89, 756-764.	0.8	71
103	Benefit of Adjuvant Brachytherapy Versus External Beam Radiation for Early Breast Cancer: Impact of Patient Stratification on Breast Preservation. International Journal of Radiation Oncology Biology Physics, 2014, 88, 274-284.	0.8	32
104	The impact of concurrent granulocyte–macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled Radiation Therapy Oncology Group 9901 trial. Quality of Life Research, 2014, 23, 1841-1858.	3.1	24
105	Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States. Journal of Urology, 2014, 192, 1650-1656.	0.4	37
106	Considerations for Observational Research Using Large Data Sets in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2014, 90, 11-24.	0.8	70
107	Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. SpringerPlus, 2014, 3, 166.	1.2	20
108	Local recurrence map to guide target volume delineation after radical prostatectomy. Practical Radiation Oncology, 2014, 4, e239-e246.	2.1	16

#	Article	IF	CITATIONS
109	Racial Disparities in Prostate Cancer–Specific Mortality in Men With Low-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e189-e195.	1.9	46
110	Risk of Late Toxicity in Men Receiving Dose-Escalated Hypofractionated Intensity Modulated Prostate Radiation Therapy: Results From a Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1074-1084.	0.8	127
111	Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: Implications for targeting the undissected axilla. Practical Radiation Oncology, 2014, 4, 116-122.	2.1	7
112	Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy, 2014, 13, 157-162.	0.5	67
113	Lymph node-positive prostate cancer: the benefit of local therapy. Oncology, 2013, 27, 655, 660-1.	0.5	1
114	Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncology, The, 2012, 13, e270-e276.	10.7	28
115	Management of Older Men With Clinically Localized Prostate Cancer: The Significance of Advanced Age and Comorbidity. Seminars in Radiation Oncology, 2012, 22, 284-294.	2.2	23
116	Screening colonoscopy before prostate cancer treatment can detect colorectal cancers in asymptomatic patients and reduce the rate of complications after brachytherapy. Practical Radiation Oncology, 2012, 2, e7-e13.	2.1	8
117	Recommendations for Post-Prostatectomy Radiation Therapy in the United States Before and After the Presentation of Randomized Trials. Journal of Urology, 2011, 185, 116-120.	0.4	78
118	How Improved Local-Regional Therapy Impacts Survival. Current Breast Cancer Reports, 2010, 2, 83-89.	1.0	1
119	Prostate Cancer Screening in Men 75 Years Old or Older: An Assessment of Self-Reported Health Status and Life Expectancy. Journal of Urology, 2010, 183, 1798-1802.	0.4	20
120	Radiation Therapy for Pediatric Central Nervous System Tumors. Journal of Child Neurology, 2009, 24, 1387-1396.	1.4	63